What is the difference between ACE-031 and AOD-9604?

ACE-031: Soluble decoy receptor for ActRIIB; sequesters myostatin, activin, and GDF-11 to remove multiple brakes on muscle and bone growth simultaneously AOD-9604: AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway.

Is ACE-031 FDA approved?

ACE-031 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

How is ACE-031 administered in research settings?

In research settings, ACE-031 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is AOD-9604 administered in research settings?

In research settings, AOD-9604 is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›ACE-031 vs AOD-9604

Peptide Comparison

ACE-031 vs AOD-9604

Name: ACE-031 vs AOD-9604 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

ACE-031

ACVR2B-Fc

PerformanceInvestigationalResearch Only

Half-life: ~14 days

7 providers listed

Full ACE-031 profile →

AOD-9604

Advanced Obesity Drug 9604

Fat LossResearch Only

Half-life: 30–60 minutes

225 providers listed

Full AOD-9604 profile →

Bottom line

ACE-031 and AOD-9604 target different goals — ACE-031 for myostatin/activin inhibition, AOD-9604 for selective fat tissue lipolysis via GH C-terminal fragment mechanism. They're compared here for reference, not as direct substitutes.

Quick Verdict

ACE-031

Half-life

~14 days

AOD-9604

Half-life

30–60 minutes

Different Goals

ACE-031 and AOD-9604 target different goals — ACE-031 for Muscle & Myostatin, AOD-9604 for GH / IGF Axis. They're compared here for reference; there isn't a single “better” choice between them.

Side-by-Side Comparison

ACE-031

AOD-9604

Mechanism Family

Muscle & Myostatin

GH / IGF Axis

Half-life

~14 days

30–60 minutes

FDA Status

investigational

nomination withdrawn

Admin Routes

subcutaneous, intravenous

subcutaneous, oral

Availability

Research Only

Providers

7 listed

225 listed

Avail. Notes

Activin receptor IIB-Fc fusion (ACVR2B decoy) by Acceleron Pharma. Phase 2 for Duchenne MD halted 2013 due to AEs (epistaxis, telangiectasia). Development discontinued. Previously held IND.

HGH fragment 176-191. Drug development terminated 2007 (Phase 3 failure). FDA GRAS notice GRN 000792 for food ingredient use only — not a drug approval. No active NDA. Research chemical.

Research Evidence

ACE-031

RCT · 1 key study · most recent 2017

AOD-9604

Animal · 1 key study · dated evidence base — most recent 2001

Research Citations

ACE-031

RCT2017 · Muscle & Nerve

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a rando…

AOD-9604

Animal2001 · Endocrinology

The effect of the growth hormone fragment AOD9604 on adipose tissue

About ACE-031

Soluble decoy receptor for ActRIIB; sequesters myostatin, activin, and GDF-11 to remove multiple brakes on muscle and bone growth simultaneously

Research Areas

myostatin/activin inhibitionmuscle mass increasebone density improvement

About AOD-9604

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

Research Areas

selective fat tissue lipolysis via GH C-terminal fragment mechanismadipose metabolism stimulation without IGF-1 elevationoriginally developed to isolate GH lipolytic effect from growth effectssubcutaneous injection — reconstitution with bacteriostatic water required

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ACE-031

Reported (Unverified — Pending Clinical Review)

cardiovascular diseasetelangiectasia riskbleeding disorderspregnancy

No established clinical contraindications

AOD-9604

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

ACE-031

$123.98/mg

$92.40 – $158.25 range

10 vendors

View price index →Find providers →

AOD-9604

$10.25/mg

$7.77 – $14.03 range

59 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

ACE-031

7 listed

Browse directory →

Providers offering

AOD-9604

225 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

Related Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated October 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ACE-031 vs AOD-9604 — Per-mg Price Comparison. Retrieved October 27, 2026, from https://peptidebase.io/peptides/compare/ace-031/aod-9604

https://peptidebase.io/peptides/compare/ace-031/aod-9604 Methodology License Download JSON Download CSV